首页 > 最新文献

International Journal of Surgery-Oncology最新文献

英文 中文
Retifanlimab: a breakthrough for the management of Merkel cell carcinoma Retifanlimab:默克尔细胞癌治疗的一个突破
IF 0.3 Pub Date : 2023-08-18 DOI: 10.1097/ij9.0000000000000116
Ayesha Shaukat, Afsheen Q Khan, Rumaisa Riaz, Ummara Batool, Abdullah Malikzai
Merkel cell carcinoma (MCC) is a rare, highly metastatic cutaneous neuroendocrine cancer originating from specialized Merkel cells, which are responsible for touch sensation in the skin. It is characterized by a firm, rapidly expanding nodule on sun-exposed skin areas, especially the head and neck. It has a high mortality rate, with reported overall survival rates ranging from 14% for distant disease to 51% for local disease. In March 2023, retifanlimab (Zynyz) received accelerated U.S. Food and Drug Administration (FDA) approval for treating adults with metastatic or recurrent locally advanced MCC. This drug offers a first-line response against MCC by improving the body’s immune response against cancer cells. This article aims to provide updated guidelines on the properties, dosing, and mechanism of action while discussing its use for the management of adults.
默克尔细胞癌(MCC)是一种罕见的,高度转移的皮肤神经内分泌癌,起源于特化的默克尔细胞,负责皮肤的触觉。它的特征是在暴露在阳光下的皮肤区域,特别是头部和颈部,形成一个坚固、迅速扩大的结节。它的死亡率很高,据报道,远端疾病的总生存率为14%,局部疾病的总生存率为51%。2023年3月,retifanlimab (Zynyz)获得美国食品和药物管理局(FDA)加速批准,用于治疗转移性或复发性局部晚期MCC的成人。这种药物通过提高人体对癌细胞的免疫反应,为MCC提供一线治疗。这篇文章的目的是提供有关属性,剂量和作用机制的最新指南,同时讨论其在成人管理中的使用。
{"title":"Retifanlimab: a breakthrough for the management of Merkel cell carcinoma","authors":"Ayesha Shaukat, Afsheen Q Khan, Rumaisa Riaz, Ummara Batool, Abdullah Malikzai","doi":"10.1097/ij9.0000000000000116","DOIUrl":"https://doi.org/10.1097/ij9.0000000000000116","url":null,"abstract":"Merkel cell carcinoma (MCC) is a rare, highly metastatic cutaneous neuroendocrine cancer originating from specialized Merkel cells, which are responsible for touch sensation in the skin. It is characterized by a firm, rapidly expanding nodule on sun-exposed skin areas, especially the head and neck. It has a high mortality rate, with reported overall survival rates ranging from 14% for distant disease to 51% for local disease. In March 2023, retifanlimab (Zynyz) received accelerated U.S. Food and Drug Administration (FDA) approval for treating adults with metastatic or recurrent locally advanced MCC. This drug offers a first-line response against MCC by improving the body’s immune response against cancer cells. This article aims to provide updated guidelines on the properties, dosing, and mechanism of action while discussing its use for the management of adults.","PeriodicalId":42930,"journal":{"name":"International Journal of Surgery-Oncology","volume":"43 1","pages":""},"PeriodicalIF":0.3,"publicationDate":"2023-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88362542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcomes of the distal rectal cancer treatment depending on the type of sphincter-sparing surgery 直肠癌远端治疗的结果取决于保留括约肌手术的类型
IF 0.3 Pub Date : 2023-07-04 DOI: 10.1097/ij9.0000000000000115
P. Gordiichuk, M. Gordiichuk
The increase in mid-ampullary and lower ampullary rectal cancer with disappointing treatment results requires ongoing discussion, research, and improvement of the complex treatment. We analyzed the results of complex treatment in 442 patients with stages II–III mid-ampullary and lower ampullary rectal cancer that underwent three types of sphincter-sparing surgeries, including low anterior resection (LAR), intersphincteric resection (ISR), and abdomino-anal resection of the rectum (AAR) at the second stage of complex treatment. There was a significant difference between groups in terms of surgery type selection based on the distance from the tumor to the dentate line. When the tumor was located at a distance of 30 mm or less from the dentate line, LAR was performed in 16.4% of cases, whereas ISR and AAR were used in 96.58 and 58.09% of cases, respectively, which is statistically significant (P<0.001). Preventive stoma was used in 78.87% of LAR, 5.9% of ISR, and 6.62% of AAR, which had a significant difference (P<0.001). In the structure of postoperative complications, a group of typical complications (ІІІ–IV) was identified for the types of operations performed. Their frequency when performing LAR was 18.2%, ISR – 7.7%, and AAR – 8.1%, which was statistically significant (P=0.003). The frequency of local recurrences, depending on the type of surgery was not statistically significant (P>0.05), but had a direct correlation with the recurrence-free survival curves. Relapse-free and overall (3 years and 5 years) survival depending on the type of sphincter-preserving surgery did not have a significant difference according to the log-rank test. The more types of surgical intervention surgeons have at their disposal, the more rational it is to select the one that will ensure the best treatment results.
中壶腹和下壶腹直肠癌的增加,治疗结果令人失望,需要持续的讨论、研究和改进复杂的治疗方法。我们分析了442例II-III期中壶腹和下壶腹直肠癌患者的综合治疗结果,这些患者在综合治疗的第二阶段接受了三种保留括约肌的手术,包括低前切除术(LAR)、括约肌间切除术(ISR)和腹肛直肠切除术(AAR)。在基于肿瘤到齿状线的距离选择手术类型方面,两组之间存在显著差异。当肿瘤位于距齿状线≤30mm时,行LAR的占16.4%,而ISR和AAR分别占96.58%和58.09%,差异有统计学意义(P0.05),但与无复发生存曲线直接相关。根据log-rank检验,根据保留括约肌手术的类型,无复发和总生存率(3年和5年)没有显著差异。外科医生拥有的手术干预类型越多,选择能够确保最佳治疗效果的手术干预类型就越合理。
{"title":"Outcomes of the distal rectal cancer treatment depending on the type of sphincter-sparing surgery","authors":"P. Gordiichuk, M. Gordiichuk","doi":"10.1097/ij9.0000000000000115","DOIUrl":"https://doi.org/10.1097/ij9.0000000000000115","url":null,"abstract":"\u0000 \u0000 The increase in mid-ampullary and lower ampullary rectal cancer with disappointing treatment results requires ongoing discussion, research, and improvement of the complex treatment.\u0000 \u0000 \u0000 \u0000 We analyzed the results of complex treatment in 442 patients with stages II–III mid-ampullary and lower ampullary rectal cancer that underwent three types of sphincter-sparing surgeries, including low anterior resection (LAR), intersphincteric resection (ISR), and abdomino-anal resection of the rectum (AAR) at the second stage of complex treatment.\u0000 \u0000 \u0000 \u0000 There was a significant difference between groups in terms of surgery type selection based on the distance from the tumor to the dentate line. When the tumor was located at a distance of 30 mm or less from the dentate line, LAR was performed in 16.4% of cases, whereas ISR and AAR were used in 96.58 and 58.09% of cases, respectively, which is statistically significant (P<0.001). Preventive stoma was used in 78.87% of LAR, 5.9% of ISR, and 6.62% of AAR, which had a significant difference (P<0.001). In the structure of postoperative complications, a group of typical complications (ІІІ–IV) was identified for the types of operations performed. Their frequency when performing LAR was 18.2%, ISR – 7.7%, and AAR – 8.1%, which was statistically significant (P=0.003). The frequency of local recurrences, depending on the type of surgery was not statistically significant (P>0.05), but had a direct correlation with the recurrence-free survival curves. Relapse-free and overall (3 years and 5 years) survival depending on the type of sphincter-preserving surgery did not have a significant difference according to the log-rank test.\u0000 \u0000 \u0000 \u0000 The more types of surgical intervention surgeons have at their disposal, the more rational it is to select the one that will ensure the best treatment results.\u0000","PeriodicalId":42930,"journal":{"name":"International Journal of Surgery-Oncology","volume":"27 1","pages":""},"PeriodicalIF":0.3,"publicationDate":"2023-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81471987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Spatial and temporal epidemiological analysis on the mortality rate of female breast cancer in Suzhou, China: 2006–2020 2006-2020年苏州市女性乳腺癌死亡率时空流行病学分析
IF 0.3 Pub Date : 2023-04-29 DOI: 10.1097/ij9.0000000000000113
Linchi Wang, Yan Lu, Chunyan Huang, Jing-yang Tang
{"title":"Spatial and temporal epidemiological analysis on the mortality rate of female breast cancer in Suzhou, China: 2006–2020","authors":"Linchi Wang, Yan Lu, Chunyan Huang, Jing-yang Tang","doi":"10.1097/ij9.0000000000000113","DOIUrl":"https://doi.org/10.1097/ij9.0000000000000113","url":null,"abstract":"","PeriodicalId":42930,"journal":{"name":"International Journal of Surgery-Oncology","volume":"95 1","pages":""},"PeriodicalIF":0.3,"publicationDate":"2023-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84002718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mucinous adenocarcinoma of the urachus: a practical overview of a broad differential diagnosis: case report 尿道粘液腺癌:一个广泛的鉴别诊断的实际概述:病例报告
IF 0.3 Pub Date : 2023-04-29 DOI: 10.1097/ij9.0000000000000114
Germán J. Sánchez, R. Guevara, A. C. Riscanevo Bobadilla, Mayra A. Hernández, R. Duarte, A. Balaguera
{"title":"Mucinous adenocarcinoma of the urachus: a practical overview of a broad differential diagnosis: case report","authors":"Germán J. Sánchez, R. Guevara, A. C. Riscanevo Bobadilla, Mayra A. Hernández, R. Duarte, A. Balaguera","doi":"10.1097/ij9.0000000000000114","DOIUrl":"https://doi.org/10.1097/ij9.0000000000000114","url":null,"abstract":"","PeriodicalId":42930,"journal":{"name":"International Journal of Surgery-Oncology","volume":"205 1","pages":""},"PeriodicalIF":0.3,"publicationDate":"2023-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72776482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of Denosumab in the Management of Giant Cell Tumor, a Cross Sectional Study 横断面研究:Denosumab在巨细胞肿瘤治疗中的作用
IF 0.3 Pub Date : 2023-01-01 DOI: 10.29337/ijsonco.146
Javeria Saeed, Zaid-Ahmed Shamsi, K. Ahmed, M. Umer
{"title":"Role of Denosumab in the Management of Giant Cell Tumor, a Cross Sectional Study","authors":"Javeria Saeed, Zaid-Ahmed Shamsi, K. Ahmed, M. Umer","doi":"10.29337/ijsonco.146","DOIUrl":"https://doi.org/10.29337/ijsonco.146","url":null,"abstract":"","PeriodicalId":42930,"journal":{"name":"International Journal of Surgery-Oncology","volume":"67 1","pages":""},"PeriodicalIF":0.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90763993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of Different Treatments for Patients with Advanced Hepatocellular Carcinoma: A System Review and Network Meta-Analysis 不同治疗方法对晚期肝细胞癌患者的疗效:系统回顾和网络meta分析
IF 0.3 Pub Date : 2022-09-20 DOI: 10.29337/ijsonco.140
Y. Ling, Meng Jin, Mei-yan Zhu, Yan Wang, Yong Chen, Zhenwei Peng
{"title":"Efficacy of Different Treatments for Patients with Advanced Hepatocellular Carcinoma: A System Review and Network Meta-Analysis","authors":"Y. Ling, Meng Jin, Mei-yan Zhu, Yan Wang, Yong Chen, Zhenwei Peng","doi":"10.29337/ijsonco.140","DOIUrl":"https://doi.org/10.29337/ijsonco.140","url":null,"abstract":"","PeriodicalId":42930,"journal":{"name":"International Journal of Surgery-Oncology","volume":"75 1","pages":""},"PeriodicalIF":0.3,"publicationDate":"2022-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85759292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunotherapy Combined with Chemotherapy in Neoadjuvant Therapy for Locally Advanced Renal Pelvis Carcinoma: A Case Report and Literature Review 免疫联合化疗在局部晚期肾盂癌新辅助治疗中的应用:1例报告及文献复习
IF 0.3 Pub Date : 2022-01-01 DOI: 10.29337/ijsonco.141
Liuting Xu, Dongxing Wang, Youyou Wu, Chunlei Zhang, Pengcheng Miao
{"title":"Immunotherapy Combined with Chemotherapy in Neoadjuvant Therapy for Locally Advanced Renal Pelvis Carcinoma: A Case Report and Literature Review","authors":"Liuting Xu, Dongxing Wang, Youyou Wu, Chunlei Zhang, Pengcheng Miao","doi":"10.29337/ijsonco.141","DOIUrl":"https://doi.org/10.29337/ijsonco.141","url":null,"abstract":"","PeriodicalId":42930,"journal":{"name":"International Journal of Surgery-Oncology","volume":"14 6","pages":""},"PeriodicalIF":0.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72462652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mutant Status of the P-53 Gene in Relation with microRNA, as an Unfavorable Marker in Breast Cancer, a Systematic Review p53基因突变状态与microRNA相关,作为乳腺癌的不利标志物,系统综述
IF 0.3 Pub Date : 2022-01-01 DOI: 10.29337/ijsonco.131
A. Udristioiu, Alexandru Giubelan, Nica-Badea Delia
{"title":"Mutant Status of the P-53 Gene in Relation with microRNA, as an Unfavorable Marker in Breast Cancer, a Systematic Review","authors":"A. Udristioiu, Alexandru Giubelan, Nica-Badea Delia","doi":"10.29337/ijsonco.131","DOIUrl":"https://doi.org/10.29337/ijsonco.131","url":null,"abstract":"","PeriodicalId":42930,"journal":{"name":"International Journal of Surgery-Oncology","volume":"82 1","pages":""},"PeriodicalIF":0.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76043071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcomes and Associated Factors Among Adult Patients Admitted to Adult Intensive Care Unit, Retrospective Cohort Study 成人重症监护病房成年患者的预后及相关因素:回顾性队列研究
IF 0.3 Pub Date : 2022-01-01 DOI: 10.29337/ijsonco.136
Z. Bekele, H. Jisha, M. Haile
{"title":"Outcomes and Associated Factors Among Adult Patients Admitted to Adult Intensive Care Unit, Retrospective Cohort Study","authors":"Z. Bekele, H. Jisha, M. Haile","doi":"10.29337/ijsonco.136","DOIUrl":"https://doi.org/10.29337/ijsonco.136","url":null,"abstract":"","PeriodicalId":42930,"journal":{"name":"International Journal of Surgery-Oncology","volume":"1 1","pages":""},"PeriodicalIF":0.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79895377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Mir-556-3p Inhibits SqCLC via NUAK1 Mir-556-3p通过NUAK1抑制SqCLC
IF 0.3 Pub Date : 2022-01-01 DOI: 10.29337/ijsonco.138
Yini Cai, Ming Fang, Gong-Ji Yao, Lingmin Liao, Long Huang
{"title":"Mir-556-3p Inhibits SqCLC via NUAK1","authors":"Yini Cai, Ming Fang, Gong-Ji Yao, Lingmin Liao, Long Huang","doi":"10.29337/ijsonco.138","DOIUrl":"https://doi.org/10.29337/ijsonco.138","url":null,"abstract":"","PeriodicalId":42930,"journal":{"name":"International Journal of Surgery-Oncology","volume":"17 1","pages":""},"PeriodicalIF":0.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74731450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
International Journal of Surgery-Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1